Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims
Up next
Author


Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer’s clinical trial.

You May Also Like
This Wall Street pro did a deep dive into Tesla’s stock — and came up empty-handed

This Wall Street pro did a deep dive into Tesla’s stock — and came up empty-handed

Tesla’s shares are overvalued, priced on hopes for robotaxis, full self-driving and…
Oil prices log worst week since February as concerns over Middle East supply risks fade

Oil prices log worst week since February as concerns over Middle East supply risks fade

Oil futures finished lower Friday — with easing concerns over potential supply…
After AMD’s AI event, this analyst says Nvidia’s stock is the better play

After AMD’s AI event, this analyst says Nvidia’s stock is the better play

Despite underperformance for AMD shares this year and major outperformance for Nvidia…

Israel hits back at Moody’s downgrade over Gaza war impact

Israeli leaders have hit back at a credit rating downgrade from Moody’s,…